EU Updated Pharmaceutical Retention Requirements
Repackagers must now maintain physical packaging samples for the entire shelf life of their products.
Updated on Sept. 24, 2026 in Consumer Goods
Live Poll
Should regulators increase the burden on pharmaceutical companies to ensure product packaging and safety compliance?
The European Union has implemented revised Annex 19 requirements, mandating stricter physical retention protocols for packaging materials used in parallel trade. These rules affect all entities involved in repackaging medicines for the EU market.
Why it matters
The update modernizes oversight for parallel-imported and distributed products, requiring businesses to adjust their compliance and storage workflows. It replaces a framework that had remained unchanged since 2006, shifting expectations for documentation and physical audit readiness.
The revision updates regulatory standards last modified in 2006, now requiring physical retention samples to be held for at least one year following the product's expiration date. The mandate applies to every individual repackaging operation performed within the EU.
The players
European Union
A political and economic union that sets standardized regulatory requirements for pharmaceutical manufacturing and distribution across member states.
The details
Under the new Annex 19, companies must physically retain packaging samples for the entire shelf life of the repackaged product. While physical retention is the default, digital alternatives are permitted only when physical storage is not reasonably possible and must comply with EU GMP Annex 11 principles. Digital records must document batch numbers, expiration dates, safety features, and braille information, requiring prior regulatory agreement for each instance.
Timeline
The original version of Annex 19 took effect in 2006.
The revised Annex 19 requirements took effect on September 24, 2026.
Market Landscape
This policy update aligns pharmaceutical supply chain oversight with the stricter data integrity standards established by EU GMP Annex 11. It marks a departure from the 2006 framework by standardizing how digital records must be maintained when physical sample retention is bypassed.
Operators must update their standard operating procedures to ensure packaging samples from every repackaging operation are securely stored for the product's full shelf life. Management should review existing agreements between trade partners to clearly define sample storage and access responsibilities.
The takeaway
The move to mandate physical retention for all repackaged items increases the operational burden for companies managing parallel trade. Operators should audit their current packaging storage facilities and verify if their digital record-keeping processes meet the updated Annex 11 integrity standards.
Further reading
For broader trends in regulatory compliance, see the latest updates in Consumer Goods.
Source note: This article includes information reported by Lab Manager.
Live Poll
Should regulators increase the burden on pharmaceutical companies to ensure product packaging and safety compliance?
